摘要
目的观察洛伐他汀对颈内动脉系统脑梗死患者急性期血清基质金属蛋白酶9（matrix metalloproteinases 9，MMP-9）水平的影响。方法将48例急性期颈内动脉系统脑梗死患者分为2组，其中洛伐他汀组（26例），常规治疗组（22例），用ELISA法分别测定治疗前后血清MMP-9水平的变化。结果（1）洛伐他汀组治疗1周后血清MMP-9水平较治疗前明显降低（P〈0．05）。而常规治疗组治疗前后血清MMP-9水平无明显差异（P〉0．05）；（2）治疗1周后洛伐他汀组血清MMP-9水平较常规治疗组明显降低（P〈0．05）。结论洛伐他汀能降低脑梗死患者急性期血清MMP-9水平，可能因此抑制了血-脑屏障的早期开放和脑水肿，从而减轻缺血性脑损伤，改善患者预后。
Objective To observe the effect of Lovastatin on the level of MMP-9in acute stage of cerebral infarction.Methods 48patients with cerebral infarction in acutestage were assigned into Lovastatin group （n=26） and control group （n=22） . Using ELISA , the levels of MMP-9 in serum were measured before and after therapy, Results （1） After 1 week of follow-up, the level of MMP-9 in serum was lower （P〈0.05） in the Lovastatin group than that in control group. （2） The level of MMP-9 in serum was lower （P〈0.05） in the Lovastatin group than that in control group after 1 week therapy.Conclusions Lovastatin can reduce the level of MMP-9 in acute stage of cerebral infarction, thus may relieve the ischemic brain injury.
